# Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer

> **NCT01969955** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 50 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of Lung

## Interventions

- **DRUG:** nanoparticle albumin-bound paclitaxel

## Key facts

- **NCT ID:** NCT01969955
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-09
- **Primary completion:** 2014-12
- **Final completion:** 2015-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2014-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01969955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01969955, "Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01969955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*